Escitalopram in clinical practice in Greece: Treatment response and tolerability in depressed patients

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 6, 2009, Pages 937-945

  Stamouli, S S ^a   Yfantis, A ^b   Lamboussis, E ^c   Liakouras, A ^d   Lagari, V ^e   Tzanakaki, M ^f   Giailoglou, D ^g   Legault, M ^g   Parashos, I A ^g  

^a UNIVERSITY OF ATHENS   (Greece)

^b Kalamata General Hospital   (Greece)

^c ATHENS NAVAL HOSPITAL   (Greece)

^d General Hospital of Korinthos   (Greece)

^e Psychiatric Hospital of Tripoli   (Greece)

^f General Hospital of Chania   (Greece)

^g H LUNDBECK A S   (Denmark)

Author keywords

CGI; Depression; Escitalopram; Response; Sheehan disability scale; Tolerability

Indexed keywords

ESCITALOPRAM; FLUOXETINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILY LIFE; FATIGUE; FEMALE; GREECE; GROUPS BY AGE; HEALTH SURVEY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; RATING SCALE; SOCIAL LIFE; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; WORK DISABILITY;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANXIETY; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; GREECE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649598264     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902810375     Document Type: Article

References (60)

1. Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry 2003;64:1091-1093
2. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005;162:836-846 (Pubitemid 40676194)
3. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999;156:5-10 (Pubitemid 29034873)
4. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002;159:469-473
5. Merikangas KR, Ames M, Cui L, et al. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry 2007;64:1180-1188 (Pubitemid 47529342)
6. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504
7. Ustun TB, Yuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-392
8. Papakostas GI, Petersen T, Mahal Y, et al. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry 2004;26:13-17 (Pubitemid 38142561)
9. Trivedi MH, Rush AJ, Wisniewski SR, et al. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry 2006;67:185-195 (Pubitemid 43357463)
10. Adler DA, McLaughlin TJ, Rogers WH, et al. Job performance deficits due to depression. Am J Psychiatry 2006;163:1569-1576 (Pubitemid 44465757)
11. Baune BT, Adrian I, Jacobi F. Medical disorders affect health outcome and general functioning depending on comorbid major depression in the general population. J Psychosom Res 2007;62:109-118 (Pubitemid 46161593)
12. Broadhead WE, Blazer DG, George LK, et al. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990;264:2524-2528
13. Lerner D, Adler DA, Chang H, et al. Unemployment, job retention, and productivity loss among employees with depression. Psychiatr Serv 2004;55:1371-1378 (Pubitemid 39577972)
14. Ormel J, Vonkorff M, Oldehinkel AJ, et al. Onset of disability in depressed and non-depressed primary care patients. Psychol Med 1999;29:847-853 (Pubitemid 29381044)
15. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989;262:914-919
16. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006;31:1841-1853 (Pubitemid 44246330)
17. Hirschfeld RM, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 2002;51:123-133 (Pubitemid 34127902)
18. Lin EH, Vonkorff M, Russo J, et al. Can depression treatment in primary care reduce disability? A stepped care approach. Arch Fam Med 2000;9:1052-1058 (Pubitemid 32014699)
19. Simon GE, Katon W, Rutter C, et al. Impact of improved depression treatment in primary care on daily functioning and disability. Psychol Med 1998;28:693-701 (Pubitemid 28241301)
20. Sanchez C, Bogeso KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004;174:163-176 (Pubitemid 38916289)
21. Burke WJ, Gergel I, Bose A. Sixty three edition. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63(4):331-336 (Pubitemid 34456361)
22. Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005;21:1659-1668 (Pubitemid 41505032)
23. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-217 (Pubitemid 36871872)
24. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-137 (Pubitemid 40571510)
25. Wade A, Michael LO, Bang HK. Escitalopram 10 mg/day is effective and well tolerated in a placebo- controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102 (Pubitemid 34442189)
26. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharm 2006;9:495-505 (Pubitemid 44607202)
27. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17:65-69 (Pubitemid 40967128)
28. Davidson JR, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004;19:234-240 (Pubitemid 39014143)
29. Fineberg NA, Tonnoir B, Lemming O, et al. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 2007;17:430-439 (Pubitemid 46497661)
30. Kasper S, Stein DJ, Loft H, et al. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005;186:222-226 (Pubitemid 40343816)
31. Lader M, Stender K, Burger V, et al. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19:241-248 (Pubitemid 39014144)
32. Stein DJ, Andersen EW, Tonnoir B, et al. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin 2007;23:701-711 (Pubitemid 46631473)
33. Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22:1331-1341 (Pubitemid 44085585)
34. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-131
35. Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006;39:180-184 (Pubitemid 44369178)
36. Anders M, Tuma I, Rosslerova H. A surveillance study of escitalopram treatment of depressed patients. Expert Opin Pharmacother 2008;9:1-6 (Pubitemid 351233743)
37. Olie JP, Tonnoir B, Menard F, et al. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress Anxiety 2007;24(5):318-324 (Pubitemid 47403481)
38. Chokka P, Legault M. Escitalopram in the treatment of major depressive disorder in primary care settings: an open-label trial. Depress Anxiety 2008;25(12):E173-81
39. Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety 2005;21:26-32 (Pubitemid 40614546)
40. Winkler D, Pjrek E, Moser U, et al. Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. Hum Psychopharmacol 2007;22:245-251 (Pubitemid 46939282)
41. Guy W. ECDEU Assessment Manual for Psychopharmacology Revised, 1976 028 Clinical Global Impressions. Revised, 1976 edition. Maryland: DHEW Publication; 1976
42. Bandelow B, Baldwin DS, Dolberg OT, et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 2006;67:1428-1434
43. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(Suppl 3):89-95 (Pubitemid 26373761)
44. Khan A, Khan SR, Shankles EB, et al. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. Int Clin Psychopharmacol 2002;17:281-285 (Pubitemid 35283715)
45. Khan A, Brodhead AE, Kolts RL. Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis. Int Clin Psychopharmacol 2004;19:157-160 (Pubitemid 38586487)
46. Muller MJ, Himmerich H, Kienzle B, et al. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord 2003;77:255-260 (Pubitemid 37377919)
47. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108 (Pubitemid 28551779)
48. Pintor L, Gasto C, Navarro V, et al. Relapse of major depression after complete and partial remission during a 2-year follow-up. J Affect Disord 2003;73:237-244 (Pubitemid 36120734)
49. Tranter R, O'Donovan C, Chandarana P, et al. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002;27:241-247 (Pubitemid 34988904)
50. Trivedi MH, Hollander E, Nutt D, et al. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry 2008;69:246-258
51. Zimmerman M, Chelminski I, Posternak M. A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. Int Clin Psychopharmacol 2004;19:1-7 (Pubitemid 38114617)
52. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 2000;57:375-380 (Pubitemid 30202328)
53. Nemeroff CB. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 2007;41:189-206 (Pubitemid 44854991)
54. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-1180
55. Ramana R, Paykel ES, Cooper Z, et al. Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med 1995;25:1161-1170
56. Tedlow J, Fava M, Uebelacker L, et al. Outcome definitions and predictors in depression. Psychother Psychosom 1998;67:266-270 (Pubitemid 28386472)
57. Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007;22:323-329 (Pubitemid 47530836)
58. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007;23:1605-1614 (Pubitemid 47122170)
59. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005;87:161-167 (Pubitemid 41039938)
60. Montgomery SA, Nil R, Durr-Pal N, et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005;66:1270-1278 (Pubitemid 41546506)